Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hersch

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 1, 1996
Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesiclesM L Gilmor, N R Nash, A Roghani, et al.
Journal of Neurochemistry|June 6, 2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic miceAlpaslan Dedeoglu, James K Kubilus, Lichuan Yang, et al.
Neuroimage. Clinical|August 10, 2018
Complex spatial and temporally defined myelin and axonal degeneration in Huntington diseaseH D Rosas, P Wilkens, D H Salat, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 7, 2002
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's diseaseRobert J Ferrante, Ole A Andreassen, Alpaslan Dedeoglu, et al.
American Journal of Medical Genetics|May 20, 1999
Tissue heterogeneity of the FMR1 mutation in a high-functioning male with fragile X syndromeA K Taylor, F Tassone, P N Dyer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 7, 2006
Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measuresH Diana Rosas, David S Tuch, Nathanael D Hevelone, et al.
Neuromolecular Medicine|July 4, 2002
Cytochrome C and caspase-9 expression in Huntington's diseaseTamara Kiechle, Alpaslan Dedeoglu, James Kubilus, et al.
Journal of Personalized Medicine|October 27, 2022
The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's DiseaseHilda T Maibach, Michael J Brownstein, Steven M Hersch, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|August 6, 1999
Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtinA S Hackam, J G Hodgson, R Singaraja, et al.
Neurobiology of Disease|October 12, 2004
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic miceFran Norflus, Agnes Nanje, Claire-Anne Gutekunst, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 1, 1996
Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesiclesM L Gilmor, N R Nash, A Roghani, et al.
Journal of Neurochemistry|June 6, 2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic miceAlpaslan Dedeoglu, James K Kubilus, Lichuan Yang, et al.
Neuroimage. Clinical|August 10, 2018
Complex spatial and temporally defined myelin and axonal degeneration in Huntington diseaseH D Rosas, P Wilkens, D H Salat, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 7, 2002
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's diseaseRobert J Ferrante, Ole A Andreassen, Alpaslan Dedeoglu, et al.
American Journal of Medical Genetics|May 20, 1999
Tissue heterogeneity of the FMR1 mutation in a high-functioning male with fragile X syndromeA K Taylor, F Tassone, P N Dyer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 7, 2006
Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measuresH Diana Rosas, David S Tuch, Nathanael D Hevelone, et al.
Neuromolecular Medicine|July 4, 2002
Cytochrome C and caspase-9 expression in Huntington's diseaseTamara Kiechle, Alpaslan Dedeoglu, James Kubilus, et al.
Journal of Personalized Medicine|October 27, 2022
The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's DiseaseHilda T Maibach, Michael J Brownstein, Steven M Hersch, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|August 6, 1999
Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtinA S Hackam, J G Hodgson, R Singaraja, et al.
Neurobiology of Disease|October 12, 2004
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic miceFran Norflus, Agnes Nanje, Claire-Anne Gutekunst, et al.
Pageof 13